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Abstract
 
Mutations in the gene encoding Bruton’s tyrosine kinase (
 
btk
 
) cause the B cell deficiency dis-
eases X-linked agammaglobulinemia (XLA) in humans and X-linked immunodeficiency (xid)
in mice. In vivo and in vitro studies indicate that the BTK protein is essential for B cell sur-
vival, cell cycle progression, and proliferation in response to B cell antigen receptor (BCR)
stimulation. BCR stimulation leads to the activation of transcription factor nuclear factor (NF)-
 
k
 
B, which in turn regulates genes controlling B cell growth. We now demonstrate that a null
mutation in 
 
btk
 
 known to cause the xid phenotype prevents BCR-induced activation of NF-
 
k
 
B. This defect can be rescued by reconstitution with wild-type BTK. This mutation also in-
terferes with BCR-directed activation of I
 
k
 
B kinase (IKK), which normally targets the NF-
 
k
 
B
inhibitor I
 
k
 
B
 
a
 
 for degradation. Taken together, these findings indicate that BTK couples IKK
and NF-
 
k
 
B to the BCR. Interference with this coupling mechanism may contribute to the B
cell deficiencies observed in XLA and xid.
Key words: X-linked immunodeﬁciency • X-linked agammaglobulinemia • antigen receptor 
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Introduction
 
Biochemical transmission of signals discharged from the B
 
cell antigen receptor (BCR)
 
1
 
 to downstream transcription
factors involves the action of multiple protein tyrosine ki-
nases (PTKs; for review see reference 1). These PTKs in-
clude Syk, Lyn, and Bruton’s tyrosine kinase (BTK),
which are induced after BCR cross-linking (2, 3). Acti-
vated BTK transduces signals that are important for the
regulation of B cell growth and proliferation (4, 5). For ex-
ample, BTK acts in concert with Syk to phosphorylate and
 
activate phospholipase C (PLC)-
 
g
 
2 (6, 7), which mediates
 
production of the second messengers inositol 1,4,5-tri-
 
phosphate and diacylglycerol (8). In turn, these second mes-
sengers stimulate the activity of protein kinase C (PKC)
and increase intracellular calcium levels, resulting in the ac-
tivation of downstream transcription factors (9, 10). How-
ever, the identities of specific transcription factors that are
controlled by BTK activity remain unknown.
 
Mutations in the 
 
btk
 
 gene result in the B cell immuno-
deficiencies X-linked agammaglobulinemia (XLA) in hu-
mans and X-linked immunodeficiency (xid) in mice (for
review see references 11 and 12). The severe B cell defi-
ciency underlying XLA is caused by a block in B cell on-
togeny at the pre-B cell stage, leading to a dramatic reduc-
tion in the levels of serum Igs (13, 14). A less severe form
of immunodeficiency occurs in mice harboring either null
or point mutations in the 
 
btk
 
 gene (15–18). In xid mice,
 
peripheral B cells are reduced in number to 
 
z
 
50% relative
to wild type. The xid B cells that remain secrete reduced
 
levels of serum IgM and IgG3, fail to respond to T cell–
 
independent type II antigens
 
,
 
 and are unable to proliferate in
response to BCR stimulation (for review see reference 19).
Recent studies indicate that the xid phenotype may arise
from defects in cell cycle progression and BCR-directed
induction of Bcl-X
 
L
 
, an antiapoptotic protein (4, 5, 20,
21). However, the mechanisms by which BTK regulates
these processes remain unclear.
Like BTK, transcription factor nuclear factor (NF)-
 
k
 
B is
activated in response to BCR stimulation and has been im-
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plicated in the regulation of Bcl-X
 
L
 
 (22). Studies with NF-
 
k
 
B–deficient B cells have identified defects in BCR-induced
survival and proliferation (23–25). Members of the NF-
 
k
 
B/
Rel family of proteins include p50/NF-
 
k
 
B1, p52/NF-
 
k
 
B2, RelA, c-Rel, and RelB, which have the capacity
to form either homo- or heterodimers (26). In quiescent
cells, NF-
 
k
 
B dimers containing the principle transactivat-
ing subunits RelA and c-Rel are found in the cytoplasmic
compartment associated with members of the I
 
k
 
B family of
inhibitors, such as I
 
k
 
B
 
a
 
 (26, 27). Upon cellular activation,
I
 
k
 
B
 
a
 
 is subject to site-specific phosphorylation, which tar-
gets the inhibitor for degradation by the ubiquitin–pro-
teasome pathway. Recent studies indicate that I
 
k
 
B
 
a
 
 is
phosphorylated by a multicomponent I
 
k
 
B kinase (IKK)
containing two catalytic subunits (IKK
 
a
 
 and IKK
 
b
 
) and
one regulatory subunit (IKK
 
g
 
; reference 27). The kinase
activity of IKK is stimulated by a large set of NF-
 
k
 
B–
inducing agents including the proinflammatory cytokines
TNF-
 
a 
 
and IL-1. Although it is clear that BCR stimula-
tion leads to the activation of NF-
 
k
 
B (28), a role for either
BTK or IKK in this B cell signal transduction pathway has
not been elucidated.
In this study, we investigated the significance of BTK in
the BCR/NF-
 
k
 
B signaling axis using a BTK-deficient B
cell line and primary B lymphocytes isolated from 
 
btk
 
2
 
/
 
2
 
mice. We demonstrate here that BTK is required for
BCR-induced degradation of I
 
k
 
B
 
a
 
 and NF-
 
k
 
B activation
in both transformed and primary B cells. Additionally,
BCR cross-linking stimulates the activity of IKK in B cells
expressing BTK, whereas BTK-deficient B cells are unable
to execute this response. We conclude that BTK couples
NF-
 
k
 
B to the BCR via a mechanism involving the action
of IKK. Interference with this coupling mechanism may
directly contribute to the B cell deficiencies observed in
XLA and xid diseases.
 
Materials and Methods
 
Mice.
 
The generation of 
 
btk-
 
deficient mice (null mutant;
 
btk
 
2
 
/
 
2
 
)
 
 
 
has been described previously (17). These mice have a
mixed genetic background of 129/Sv 
 
3 
 
C57BL/6. For wild-type
controls, 129/Sv 
 
3 
 
C57BL/6 or C57BL/6 mice (The Jackson
Laboratory) were used. All mice that were used as the source of
splenocytes were treated humanely and in accordance with the
federal and state government guidelines, and their use was ap-
proved by the institutional animal committee.
 
Cells.
 
The chicken DT40 cell line and DT40 cells made defi-
cient for BTK by homologous recombination (DT40.BTK; ref-
erence 6; T. Kurosaki, Riken Cell Bank, Japan) were maintained
in RPMI with 10% FCS, 1% chicken serum, 50 
 
m
 
M 2-ME, 2
mM 
 
l
 
-glutamine, and penicillin/streptomycin at 39
 
8
 
C in 5%
CO
 
2
 
. DT40 or DT40.BTK B cells were cultured in low serum
media (RPMI with 0.5% FCS, 0.05% chicken serum, 50 
 
m
 
M
2-ME, 2 mM 
 
l
 
-glutamine, and 1% penicillin/streptomycin) for
8–12 h before activation.
Cells were either left unstimulated or stimulated with 1:2 dilu-
tion of hybridoma supernatants containing anti–chicken IgM
mAb (M4) or PMA and ionomycin, 1 
 
m
 
M each (Calbiochem).
These low serum culture conditions were established to reduce
 
the levels of constitutive nuclear NF-
 
k
 
B activity (29, 30) and en-
hance the detection of the BCR-directed increases in nuclear
NF-
 
k
 
B.
For primary B cell purification, single-cell suspensions were
prepared from pooled spleens of control and 
 
btk
 
2
 
/
 
2
 
 mice. The
cell suspensions were then depleted of RBCs by density gradient
centrifugation on lympholyte-M (Cedarlane Labs.). B cells were
purified by a process of negative selection on an affinity chroma-
tography column (Cedarlane). CD4
 
1
 
CD8
 
1
 
 T cells as well as
monocytes and macrophages are removed by the column based
on their binding to antibodies against CD4, CD8, and MAC-1.
The purity of B cells isolated in this manner was between 90 and
95% for wild type and 85 and 90% for 
 
btk
 
2
 
/
 
2
 
, as confirmed
by FACS
 
®
 
 analysis using anti-B220 and anti-IgM antibodies
(PharMingen). The entire procedure was performed at 4
 
8
 
C, and
the cells were used in experiments immediately thereafter.
Purified B cells (3–5 
 
3 
 
10
 
6
 
 cells per sample) were incubated
with 10 
 
m
 
g/ml polyclonal goat anti–mouse IgM F(ab
 
9
 
)
 
2 
 
fragments
(Jackson ImmunoResearch) or with PMA and ionomycin (1 
 
m
 
M
each) for 2 h at a cellular density of 2 
 
3 
 
10
 
6
 
 cells per milliliter in
culture media (RPMI-1640 supplemented with 10% serum). To
monitor any effects of serum on the activation of NF-
 
k
 
B, cells
that were not stimulated were also incubated in medium contain-
ing 10% serum for the duration of stimulation.
 
Electrophoretic Mobility Shift Assays and Western Blot Analysis.
 
Nuclear extracts were prepared by solubilization of cells in lysis
buffer (10 mM Hepes, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1
mM EGTA, 0.4% NP-40, 1 mM dithiothreitol [DTT], 0.5 mM
PMSF, 5 
 
m
 
g/ml antipain, 5 
 
m
 
g/ml aprotinin, 5 
 
m
 
g/ml leupeptin,
0.5 
 
m
 
g/ml pepstatin, 7.5 
 
m
 
g/ml bestatin, 4 
 
m
 
g/ml phosphorami-
don, 5 
 
m
 
g/ml soybean trypsin inhibitor) to remove the cytoplas-
mic fraction. Extracts were prepared from nuclear pellets in high
salt nuclear extraction buffer (20 mM Hepes, pH 7.9, 0.4 M
NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF)
containing protease inhibitors (31). For electrophoretic mobility
shift assays (EMSAs), 
 
a
 
-[
 
32
 
P]dCTP and 
 
a
 
-[
 
32
 
P]dATP and labeled
double-stranded oligonucleotide probe derived from the 
 
k
 
B en-
hancer element of the IL-2R
 
a
 
 receptor promoter (5
 
9
 
-CAACG-
GCAGGGGAATTCCCCTCTCCTT-3
 
9
 
; 
 
k
 
B binding site
underlined) was used (32). To determine the specificity of nucle-
oprotein binding to DNA, an oligonucleotide (5
 
9
 
-CTAC
 
AT
 
-
 
TC
 
ATTTCCAG
 
ATTCACTTTCCTGCAGT-39; kB binding
site underlined and mutations shown in bold) containing two
mutant  kB sites derived from sequences within the HIV long ter-
minal repeat (33) was used. To verify equal amounts and integrity
of proteins in the nuclear extracts, a control oligonucleotide for
NF-Y was used (34). DNA binding reactions were performed on
nuclear extracts from equal numbers of cells and 1 ml of 32P-
labeled probe in a buffer containing 20 mM Hepes, pH 7.9, 50
mM KCl, 5% glycerol, 1 mM EDTA, pH 8.0, 10 mM DTT, 1%
NP-40, 1 mg/ml BSA, 2 mg double-stranded poly(dI-dC), and 2
mg pd(N)6 random hexamer. Reactions were incubated on ice for
15 min, and the nucleoprotein–DNA complexes were resolved
on a 5% native polyacrylamide gel electrophoresed in 13 Tris
borate buffer (TBE) at 180 V for 2.5 h and visualized by autora-
diography.
For Western blot analysis of various kB family members, nu-
clear extracts equivalent to 2 3 107 cells were denatured in Laem-
mli reducing buffer by boiling at 958C for 3 min, and the proteins
were resolved by 15% SDS-PAGE. Proteins were electrotrans-
ferred onto nitrocellulose membranes and subjected to immuno-
blotting with rabbit polyclonal antibodies against RelA, c-Rel, or
SP1 in blocking solution containing 13 TBST (Tris-buffered sa-1747 Petro et al.
line and 0.1% Tween) and 5% nonfat dry milk. The bound anti-
bodies were revealed by horseradish peroxidase–conjugated goat
anti–rabbit IgG antibody (Zymed Laboratories), followed by en-
hanced chemiluminescent detection (Pierce Chemical Co.) on
autoradiography film.
For IkBa degradation assays, cells were preincubated for 30
min in medium containing 50 mM cycloheximide (4 3 106 cells
per sample) and then stimulated with anti-IgM or with PMA and
ionomycin for 90 min in the continued presence of cyclohex-
imide. After stimulation, whole cell extracts were resolved on a
12% denaturing SDS-PAGE, blotted onto nitrocellulose mem-
branes, and probed with rabbit anti–chicken IkBa (35).
Plasmid Constructs and Luciferase Assays. The coding sequence
of mouse BTK cDNA was amplified using high fidelity Pwo
DNA polymerase (Boehringer Ingelheim) using primer 59-
CTGCCATGGCTGCAGTGATACTG-39 containing a NcoI
(underlined) with primer 59-CCGGATCCTCAGGATTCT-
TCATCCATC-39 containing a BamHI (underlined) site. The
PCR product was digested with NcoI and BamHI and cloned
into the retroviral vector pMMP (reference 36; a gift of Drs. R.
Mulligan and J.-S. Lee, Harvard Medical School, Boston, MA).
Ectopic expression of protein of the appropriate size was con-
firmed by transfection into a btk2/2 Abelson pre-B cell line fol-
lowed by Western blotting using rabbit polyclonal anti-BTK an-
tibodies (17). The kB reporter plasmid encoding firefly luciferase
under the control of a promoter containing six consensus NF-kB
binding sites (6kB) and a control vector containing a Renilla lu-
ciferase gene fused to a thymidine kinase promoter were gifts
from Dr. E. Oltz (Vanderbilt University).
DT40 and DT40.BTK were each cotransfected by electropo-
ration (250 V, 960 mF; Bio-Rad Gene Pulser) with 1.5 mg of ei-
ther pMMP.BTK or pMMP (36), 5 mg of the 6kB reporter con-
struct, and 2.5 mg of the Renilla construct and cultured for 12 h
in the medium described above. Cells were also cultured in low
serum conditions for 6 h before stimulation and activated for 6 h
as described above. Activated cells were then harvested, and lev-
els of both firefly and Renilla luciferase were determined using a
Dual-Luciferase Reporter Assay System (Promega Corp.). Levels
of firefly luciferase expression were normalized against Renilla as
a control for transfection efficiency.
In Vitro Kinase Assays. In vitro kinase assays were performed
on the cytosolic protein extracts from 3–5 3 106 purified B cells.
Resting and stimulated cells were solubilized in lysis buffer con-
taining 1.5 mM MgCl2, 300 mM sucrose, and the phosphatase
inhibitors NaF (2 mM), Na3Vo4 (100 mM), and 12.5 mM
b-glycerophosphate in addition to its constituents described above.
The lysates were cleared at 14,000 rpm in a microcentrifuge for
5 min. Cleared cell extracts from 0.5 3 106 cell equivalents were
removed for Western blot analysis, and the remaining cell extract
was subjected to immunoprecipitation with anti-IKKa and anti-
IKKb antibodies (Santa Cruz Biotechnology) for 1 h on ice and
an additional 1 h with rotation after the addition of 20 ml of pro-
tein A–Sepharose beads (Amersham Pharmacia Biotech). The
immunocomplexes were washed three times in lysis buffer, fol-
lowed by one wash in kinase buffer made up of 20 mM Hepes,
pH 7.2, 2 mM MgCl2 and MnCl2, 1 mM DTT, 20 mM ATP,
and the phosphatase inhibitors described above but without
g-[32P]ATP and the substrate. The immunocomplexes were
then resuspended in 20 ml of kinase buffer containing 1.0 mCi
g-[32P]ATP and either 50 mg/ml of wild-type GST-IkBa sub-
strate or mutant GST-IkB in which Ser-32 and Ser-36 were re-
placed with Ala (GST-IkBa-SS/AA). The reaction was allowed
to continue for 30 min at 308C under agitation and then was ter-
minated by the addition of 43 SDS sample buffer. The samples
were then boiled for 10 min and resolved by 8% SDS-PAGE.
The gel was stained with Coomassie brilliant blue to visualize the
GST-IkB substrate. The gels were dried and exposed to X-ray
film to visualize g-32P–phosphorylated GST-IkB.
Results
Btk Is Required for BCR-induced Activation of NF-kB.
Prior studies have demonstrated that NF-kB is activated in
murine B cells after BCR stimulation (28, 37). Further-
more, both BTK- and NF-kB–deficient B cells exhibit
profound defects in BCR-induced survival and prolifera-
tion (24, 25). However, a biochemical link between BTK
and NF-kB has not been established. To investigate the
role of BTK in the activation of NF-kB complexes, we
employed a BTK-deficient chicken B cell line derived
from transformed DT40 cells by homologous recombina-
tion. Mutant chicken B cells lacking BTK (DT40.BTK)
and parental DT40 B cells were exposed to anti-IgM anti-
bodies that induce BCR signaling. Nuclear extracts were
then prepared and analyzed for their content of NF-kB
DNA binding activity in EMSAs. As shown in Fig. 1 A,
BCR stimulation of DT40 B cells led to a marked increase
in nuclear NF-kB activity (compare lanes 1 and 3). In sharp
contrast, the BCR-inducible activity of NF-kB in DT40.
BTK B cells was negligible (Fig. 1 A, lanes 2 and 4). The
observed defect was not apparent when DT40.BTK cells
were stimulated with combinations of phorbol ester (PMA)
and calcium ionophore (ionomycin), which together mimic
the second messengers responsible for PKC activation and
calcium mobilization (Fig. 1 A, lanes 5 and 6). These results
strongly suggest that BTK is required for BCR-induced ac-
tivation of NF-kB.
To extend the prior findings, we next compared the ki-
netics of NF-kB activation in DT40 and DT40.BTK B
cells over a period of 4 h. As shown in Fig. 1 B, NF-kB
DNA binding activity was clearly evident in the nuclear
compartment of DT40 cells after 15 min of stimulation.
This activity was still detectable after 4 h. In contrast,
DT40.BTK B cells failed to elicit any increase in the NF-
kB DNA binding activity throughout the same time
course. As such, the defect in NF-kB activity observed
with DT40.BTK B cells cannot be attributed to a delay in
its kinetics of induction.
To confirm this interpretation, we initiated further stud-
ies to determine the specificity of the DNA binding pro-
teins detected in EMSA. For these experiments, EMSAs
were conducted with the same nuclear extracts as in Fig. 1
A, a radiolabeled kB consensus sequence, and an excess of
unlabeled oligonucleotides containing either wild-type or
mutated versions of this kB sequence (30). As shown in
Fig. 1 C, nucleoprotein complex formation was completely
blocked in DNA binding reactions containing wild-type
kB oligonucleotides (lanes 3 and 6). In contrast, these nu-
cleoprotein complexes were readily detected in reactions
containing equivalent amounts of the mutant kB oligonu-
cleotide (lanes 4 and 7). These results indicate that the in-1748 BTK Mediates BCR-directed NF-kB Activation
ducible DNA binding activity observed in DT40 B cells
after engagement of the BCR is specific for kB core se-
quences.
To complement these findings, we attempted to rescue
the NF-kB defect in DT40.BTK B cells. For these studies,
we transfected DT40 and DT40.BTK B cells with an ex-
pression vector encoding wild-type BTK along with an
NF-kB reporter gene. As shown in Fig. 1 D, expression of
the NF-kB–responsive gene was significantly induced in
DT40 B cells in the absence of ectopic BTK, whereas
DT40.BTK cells failed to elicit this response. However,
enforced expression of ectopic BTK fully reconstituted
NF-kB directed transcription in DT40.BTK B cells. These
rescue experiments indicate that BTK is required for NF-
kB activation in response to BCR stimulation.
Prior studies have shown that RelA and c-Rel are the
principle transactivator subunits of NF-kB in B cells (38).
To analyze the nuclear contents of RelA and c-Rel in
DT40 cells, immunoblotting experiments with DT40 nu-
clear extracts and Rel subunit–specific antibodies were per-
formed. As shown in Fig. 2, nuclear accumulation of both
RelA and c-Rel was evident in parental DT40 B cells after
stimulation with anti-IgM antibodies (Fig. 2, lane 3, top
and center panels), whereas this response was not apparent
in DT40.BTK cells (Fig. 2, lane 4, top and center panels).
In the absence of BCR stimulation, BTK-deficient B cells
expressed lower basal levels of nuclear RelA relative to
BTK-expressing controls (Fig. 2, lane 2, top and center
panels). These differences could not be attributed to varia-
tions in nuclear extract integrity, because similar amounts of
Figure 1. Defective NF-kB activation in BTK-deficient (DT40.BTK) B cells upon BCR stimulation. (A) EMSA analysis of nuclear NF-kB in DT40
and DT40.BTK B cells. Cells were incubated for 2 h in the presence or absence of anti-IgM (lanes 1–4) or PMA/ionomycin (lanes 5 and 6), and nuclear
extracts equivalent to 4 3 106 cells were added in a reaction containing a 32P-labeled oligonucleotide probe derived from the kB enhancer element of the
IL-2Ra promoter. DNA–nucleoprotein complexes were resolved on nondenaturing polyacrylamide gels. Binding of nucleoprotein complexes to an
NF-Y probe (34) was also performed to verify the integrity and the concentration of proteins in the nuclear extracts (bottom panel). (B) Kinetics of NF-
kB activation in DT40 and DT40.BTK B cells upon IgM stimulation. Nuclear extracts were prepared and subjected to EMSA as described in A. (C) NF-
kB nucleoprotein complexes in DT40 B cells bind specifically to a consensus NF-kB site. EMSAs were conducted with the same nuclear extracts as in A.
Nuclear extracts were either preincubated with 100-fold excess of unlabeled wild-type (lanes 3 and 6), mutant NF-kB probe (Mut; lanes 4 and 7; refer-
ence 32), or without the unlabeled probes (lanes 1, 2, and 5) before addition of a 32P-labeled wild-type probe. Protein integrity and concentration in the
nuclear extracts was verified with NF-Y probe (bottom panel). (D) Ectopic expression of BTK restores BCR-directed NF-kB activation in DT40.BTK
B cells. DT40 and DT40.BTK B cells were transiently cotransfected with an expression vector encoding wild-type BTK (pMMP.BTK), an NF-kB re-
porter plasmid (6kB), and a Renilla luciferase plasmid to normalize for transfection efficiency. Control transfections were performed with blank vector
(pMMP). After 24-h culture, cells were stimulated with anti-IgM for 6 h and then assayed for reporter gene activity as described in Materials and Meth-
ods. Results for these rescue experiments are reported as the mean fold induction of NF-kB–directed transcription relative to unstimulated DT40 cells.1749 Petro et al.
the constitutively expressed transcription factor SP1 were
detected in all samples (bottom panel). Consistent with the
results shown in Fig. 1 A, nuclear translocation of RelA and
c-Rel in response to PMA/ionomycin was unaffected by
the loss of BTK (Fig. 2, lanes 5 and 6). These findings indi-
cate that the kB-specific DNA binding activity found in the
nuclei of DT40 cells after BCR engagement involves BTK-
dependent translocation of the RelA and c-Rel transactivat-
ing subunits of NF-kB to this subcellular compartment.
BTK Is Required for BCR-induced Degradation of IkBa.
In resting lymphocytes, NF-kB is typically found in the cy-
toplasmic compartment by virtue of its interaction with in-
hibitory members of the IkB family of proteins. One of
these inhibitors, termed IkBa, is degraded in response to
many NF-kB–inducing agents (27). Because IkBa degra-
dation reveals the nuclear localization signal of the Rel
dimers, NF-kB is rapidly mobilized to the nuclear com-
partment, where it stimulates transcription of many growth-
related genes as well as the gene encoding IkBa. To deter-
mine whether BCR-mediated activation of NF-kB involves
the degradation of IkBa, the stability of this inhibitor in
DT40 versus DT40.BTK cells was compared after BCR
engagement. In these experiments, cells were first exposed
to cycloheximide to prevent de novo synthesis of IkBa.
Translationally arrested cells were then treated with anti-
IgM for various periods of time. Consistent with the find-
ing that NF-kB is activated in response to BCR signaling
(Fig. 1), stimulation of wild-type DT40 B cells with anti-
IgM resulted in the rapid degradation of IkBa (Fig. 3, lanes
2–4). In sharp contrast, under the same stimulatory condi-
tions, IkBa escaped proteolytic breakdown in DT40.BTK
B cells (Fig. 3, lanes 7–9). In contrast, treatment with PMA
together with ionomycin led to the rapid loss of IkBa in
the DT40.BTK cells (Fig. 3, lanes 5 and 10). Taken to-
gether, these findings indicate that BTK mediates the nu-
clear translocation of RelA and c-Rel via a mechanism in-
volving the proteolytic inactivation of IkBa.
Interference with NF-kB and IKK Signaling in Primary btk2/2
B Cells. To ascertain the in vivo significance of our find-
ings with transformed chicken B cells, we next monitored
the status of NF-kB in primary B cells derived from btk2/2
mice. For these studies, wild-type and btk2/2 B cells were
stimulated with anti–mouse IgM F(ab9)2 antibodies, and
the corresponding nuclear extracts were analyzed for NF-
kB DNA binding activity using EMSAs. As shown in Fig.
4, NF-kB activity was substantially increased in primary
wild-type B cells after BCR cross-linking (lanes 1 and 3).
In contrast, NF-kB induction in response to BCR engage-
ment was negligible in btk2/2 B cells (Fig. 4, lanes 2 and 4).
Importantly, btk2/2 B cells were fully competent for NF-
kB signaling after stimulation with combinations of PMA
and ionomycin (Fig. 4, lanes 2 and 6). These results with
primary B cells fully recapitulate results obtained with
Figure 2. BTK-deficient B cells fail to translocate RelA and c-Rel to
the nucleus in response to BCR stimulation. Western blot analysis of RelA
and c-Rel in nuclear extracts of DT40 or DT40.BTK B cells. Nuclear ex-
tracts were prepared from cells that were either not stimulated (lanes 1 and
2) or stimulated either with anti-IgM (lanes 3 and 4) or with PMA/iono-
mycin (lanes 5 and 6). Equal amounts of nuclear extracts (2 3 107 cell
equivalents per lane) were resolved by SDS-PAGE and transferred to ni-
trocellulose membranes. The relative amounts of RelA and c-Rel were
then determined by immunoblotting using antisera directed against either
RelA (top panel) or c-Rel (center panel) and visualized by enhanced
chemiluminescence detection. The blots were stripped and reprobed for
SP1, a constitutively expressed transcription factor to ensure protein integ-
rity and the loading equivalent amounts in each lane (bottom panel).
Figure 3. A requirement for BTK in B cells for the degradation of
IkBa in response to BCR cross-linking. Western blot analysis of IkBa in
cytoplasmic extracts from DT40 (lanes 1–5) or DT40.BTK (lanes 6–10).
Cells were pretreated with cycloheximide (50 mM) for 30 min to arrest
translation. Translational arrest cells were stimulated with anti-IgM or
PMA/ionomycin for indicated time periods. Equal amounts of cytosolic
extracts (4 3 106 cell equivalents per lane) were subjected to immunoblot
analysis as described in Fig. 2 with an antiserum against chicken IkBa
(pp40). Blots were stripped and reprobed for a constitutively expressed
protein, p38 MAPK, to verify protein integrity and the loading amount
of protein in each lane (bottom panel).
Figure 4. Impaired NF-kB nuclear translocation in btk2/2 primary B
cells in response to BCR stimulation. EMSA analyses for kB binding ac-
tivity in the nuclear extracts from anti-IgM– and PMA/ionomycin-stimu-
lated B cells. Purified splenic B cells from btk2/2 or C57Bl6 (WT) mice
(WT, 93%; btk2/2, 85%; B2201/IgM1 B cell) were either left unstimu-
lated (lanes 1 and 2) or stimulated for 1 h with anti–mouse F(ab9)2 (lanes 3
and 4) or with PMA and ionomycin (lanes 5 and 6). Equal amounts of nu-
clear extracts (3 3 106 cell equivalents per lane) were used in each DNA
binding reaction. NF-Y binding was used as a control to verify the integ-
rity and concentration of proteins in the nuclear extracts. Based on quan-
titative analysis of three separate experiments, the mean fold induction of
NF-kB DNA binding activity normalized by their NFY controls in WT
versus btk2/2 cells was 1.7 6 0.3 and 1.0 6 0.1, respectively.1750 BTK Mediates BCR-directed NF-kB Activation
transformed DT40 cells, providing further evidence that
the linkage between NF-kB and the BCR via BTK is
physiologically significant.
Experiments shown in Fig. 3 indicate that BTK is re-
quired for BCR-induced degradation of IkBa, a major
cytoplasmic inhibitor of NF-kB. In response to proinflam-
matory cytokines, IkBa is phosphorylated at Ser-32 and
Ser-36 by a multicomponent IKK. In turn, this phosphory-
lation event targets IkBa to the ubiquitin–proteasome
pathway. To determine whether IKK is under BTK control
in primary B cells, in vitro phosphorylation assays were per-
formed using a GST-IkBa (amino acids 1–54) fusion pro-
tein as a substrate (39). Wild-type and btk2/2 B cells were
stimulated with anti–mouse IgM F(ab9)2 antibodies, and en-
dogenous IKKa was immunoprecipitated. These immuno-
complexes were then incubated with the GST-IkBa sub-
strate and g-[32P]ATP. As shown in Fig. 5 A, IKK activity
was significantly upregulated in primary B cells expressing
BTK after BCR cross-linking (lanes 1 and 3). In contrast,
btk2/2 B cells failed to elicit this IKK response (lanes 2 and
4). The lack of IKK response could not be attributed to its
absence, changes in the steady state levels (Fig. 5 A, bottom
panel), or defective enzymatic activity, as this response was
rescued when BTK-deficient cells were treated with PMA
and ionomycin (lanes 7 and 8), a combination that potently
activates NF-kB via a BTK-independent mechanism (Fig.
4). Importantly, the IKK activity detected in these experi-
ments was specific for Ser-32 and Ser-36 of IkBa, because
replacement of both sites with Ala in the GST-IkBa sub-
strate eliminated phosphoryl group transfer (Fig. 5, lanes 5
and 6; reference 31). Similar results were obtained with
IKKb immunoprecipitates (Fig. 5 B). However, we cannot
discern whether IKKa or IKKb is selectively activated after
BCR stimulation, because these catalytic subunits interact
in the context of a multicomponent holoenzyme. Collec-
tively, these findings with primary btk2/2 B cells demon-
strate that BTK functions to mediate IKK activation upon
BCR engagement, indicating that IKK is positioned down-
stream of BTK in the BCR signaling pathway.
Discussion
Mutations that inactivate BTK cause the B cell defi-
ciency diseases XLA in humans and xid in mice. Prior stud-
ies have established that BTK is activated upon BCR stim-
ulation and functions to regulate B cell survival and
growth. However, the precise mechanisms by which BTK
mediates these biological responses remain unknown. In
this regard, recent studies indicate that BCR stimulation
also leads to the activation and nuclear translocation of NF-
kB, which controls the expression of multiple growth-
related genes at the level of transcription (26, 40). We have
discovered that BCR-directed activation of NF-kB is im-
paired in both transformed and primary B cells that are de-
ficient for BTK. Importantly, the loss of BTK correlates
with a defect in the nuclear translocation of RelA and
c-Rel, the primary transactivating subunits of NF-kB in B
cells. Consistent with this, we have found that NF-kB
DNA binding activity accumulates in the nuclei of wild-
type B cells after BCR stimulation, whereas this response is
significantly reduced in BTK-deficient cells. Furthermore,
this activity is restored upon reconstitution with wild-type
BTK. These findings strongly suggest that BTK couples
NF-kB to the BCR.
At the present juncture, little is known about the genes
downstream of the BCR that function to regulate B cell
growth and survival. Our finding that BTK is required for
BCR-induced activation of NF-kB provides new mecha-
nistic insights into this issue. Specifically, BCR-induced
upregulation of the antiapoptotic protein Bcl-XL is im-
paired in BTK-deficient B cells, which may explain the re-
duced number of B cells in xid mice (our unpublished re-
Figure 5. btk2/2 B cells fail to activate IKKa and IKKb in response to
BCR stimulation. (A) primary B cells from spleens of btk2/2 and C57Bl6
(WT) mice were purified and stimulated as in Fig. 4. Cells were either left
unstimulated (lanes 1 and 2) or stimulated for 30 min with anti–mouse
IgM F(ab9)2 (lanes 3 and 4) or with PMA and ionomycin (lanes 7 and 8).
Cytosolic extracts from 3 3 106 cells per sample were immunoprecipi-
tated with antibodies directed against IKKa (Santa Cruz Biotechnology),
and the resulting immunocomplexes were subjected to in vitro kinase as-
say containing g-[32P]ATP and 1.0 mg of GST-IkBa as the substrate. To
determine the specificity of the kinase activity on the IkBa substrate, a
mutant GST-IkBa in which Ser-32 and Ser-36 were replaced with Ala
(SS/AA) was used (lanes 5 and 6). The kinase assays were resolved by
SDS-PAGE and visualized by autoradiography. The immunoblots with
anti-IKKa (A, bottom panel) were performed on 10% of the cell extract
that was used in in vitro kinase assay to monitor the integrity and the
steady state levels of IKKa protein. (B) IKKb activity was also determined
on the same cytosolic extracts as in A, and both the IKKb kinase activity
(B, top panel) and the IKKb protein are shown (B, bottom panel).1751 Petro et al.
sults and references 4 and 40). It is well established that this
survival gene is under NF-kB control (4, 22, 41). In addi-
tion, recent studies have demonstrated that NF-kB is re-
quired for induction of the gene encoding transcription
factor Oct-2 in response to bacterial LPS, a polyclonal B
cell mitogen (42). Consistent with the BTK pathways, in-
activation of the gene encoding Oct-2 by homologous re-
combination leads to defects in BCR-directed proliferation
(43). This relationship raises the possibility that interference
with NF-kB–directed expression of Oct-2 may also con-
tribute to the observed B cell deficiency in xid mice.
Prior biochemical experiments have demonstrated that
NF-kB is regulated by the serine kinases IKKa and IKKb,
which constitute the catalytic subunits of a multicompo-
nent IKK complex. In response to proinflammatory cyto-
kines, IKK targets NF-kB inhibitor IkBa for proteolysis via
site-specific phosphorylation (27). (In the present study, we
have established that the IKK complex is activated in re-
sponse to BCR signaling.) Our studies suggest that IKK is a
signal transducer in BCR signaling pathways. However,
the activity of IKK is only modestly stimulated in this cellu-
lar background, perhaps reflecting IKK-independent mech-
anisms for NF-kB activation downstream of the BCR.
Consistent with (this finding) an involvement of IKK, we
have shown that BCR stimulation also leads to the degra-
dation of IkBa in cells expressing BTK (Fig. 3). However,
both of these signaling events are impaired in BTK-defi-
cient B cells (Figs. 3 and 5), indicating that IKK couples
BTK to NF-kB in the BCR signaling pathway. Because
BTK functions as a tyrosine-specific kinase (2, 3), it seems
unlikely that IKK is phosphorylated directly by BTK. In-
stead, we propose that BTK is required for the activation of
an upstream IKK kinase (for review see reference 26).
At least three kinases have been implicated in the activa-
tion of NF-kB at the level of IKK phosphorylation. Two
of these enzymes, MEKK1 (mitogen-activated protein
kinase kinase 1) and NIK (NF-kB–inducing kinase), are
members of the mitogen-activated protein kinase
(MAP3K) family (27). The third is a serine/threonine ki-
nase called AKT/protein kinase B (PKB), which binds and
phosphorylates IKK (44, 45). Recently, Craxton et al. (46)
showed that BCR-mediated ATK activation is impaired in
DT40.BTK B cells. Thus, BTK may stimulate IKK activity
via an AKT-dependent pathway. In addition, we consider
the involvement of PKC and calcineurin in the activation
of this upstream kinase likely because inhibition of either
PKC activity or calcium influx impairs antigen receptor–
induced NF-kB activation (results not shown; references
47–49). Indeed, both of these enzymes are activated by the
second messengers inositol 1,4,5-triphosphate and diacyl-
glycerol, which are generated by PLC-g2 in response to
the sequential action of Syk and BTK (for review see refer-
ence 12). Full resolution of these important missing links
in the BTK–NF-kB coupling mechanism awaits further
studies.
In summary, our study demonstrates that BTK-deficient
B cells are defective for BCR-induced activation of IKK,
which targets the NF-kB inhibitor IkBa for proteolysis in
BTK-expressing B cells. In turn, interference with the sig-
nal-dependent degradation of IkBa in BTK-deficient cells
prevents the nuclear translocation of RelA and c-Rel, the
principle transactivating subunits of NF-kB. In what may
be a related finding, primary B cells lacking c-Rel fail to
proliferate in response to anti-IgM stimulation (27). Taken
together, these biochemical results indicate that BTK cou-
ples IKK, IkBa, and NF-kB to the BCR. Interference
with this coupling mechanism may contribute to the B cell
deficiencies observed in XLA and xid.
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